Compounds > azacitidine

azacitidine and Multiple Myeloma

azacitidine has been researched along with Multiple Myeloma in 61 studies

Research

Studies (61)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.64)18.7374
1990's0 (0.00)18.2507
2000's19 (31.15)29.6817
2010's37 (60.66)24.3611
2020's4 (6.56)2.80

Authors

AuthorsStudies
Fu, HY; Liao, B; Qi, Y; Shen, JZ; Xu, CB1
Ding, X; Du, C; Gao, C; Huang, H; Sui, W; Wang, Y; Zhang, Y1
Feng, X; Huang, J; Meng, F; Nie, S; Wang, W; Yan, X; Zhang, L; Zhuang, L1
Bobin, A; Frouin, E; Hainaut, E; Masson Regnault, M; Plume, MA; Sibaud, V1
Albayrak, M; Falay, M; Han, U; Maral, S; Ozturk, HBA; Sahin, O1
Nohgawa, M; Oka, S; Ono, K1
Chan, GC; Chim, CS; Li, Z; Wong, KY1
Thakral, B; Wang, SA1
Asmar, F; Christensen, J; Dimopoulos, K; Fibiger Munch-Petersen, H; Gimsing, P; Grønbaek, K; Hermansen, NEU; Liang, G; O'Connel, C; Sjö, L; Sommer Kristensen, L; Søgaard Helbo, A1
Amiot, M; Chiron, D; Descamps, G; Djamai, H; Gillardin, PS; Le Gouill, S; Lucani, B; Maiga, S; Moreau, P; Moreau-Aubry, A; Pellat-Deceunynck, C; Tessoulin, B1
Bergin, K; Bowen, KM; Couto, S; Guzman, R; Kalff, A; Khong, T; Mithraprabhu, S; Ren, Y; Reynolds, J; Spencer, A; Thakurta, A; Wang, M1
Cong, H; Jin, CJ; Ju, SQ; Qi, J; Shen, XJ; Shi, LY; Wu, Y; Yuan, J1
Brown, CO; Fitzgerald, MP; Goel, A; Salem, K; Schibler, J; Singh, N; Zhan, F1
Brioli, A; Davies, FE; Johnson, DC; Kaiser, MF; Melchor, L; Mirabella, F; Morgan, GJ; Walker, BA; Wardell, CP; Wu, P1
Atadja, P; Banks, KM; Bergsagel, PL; Chesi, M; Doyle, MA; Ellul, J; Faulkner, D; Johnstone, RW; Lefebure, M; Matthews, GM; Shortt, J; Vidacs, E1
Bruyer, A; Goldschmidt, H; Hose, D; Klein, B; Moreaux, J; Veyrune, JL1
Cui, ZG; Feng, XQ; Guo, J; Liu, SG; Meng, FJ; Nie, SM; Shi, X; Su, Z; Zhang, L; Zhao, CT1
Du, H; Hu, X; Huang, J; Jiang, H; Xuan, H1
De Bruyne, E; De Raeve, H; De Smedt, E; Lemaire, M; Maes, K; McClue, S; Menu, E; Van Valckenborgh, E; Vanderkerken, K1
Ghobrial, IM; Glavey, S; Jiang, B; Leleu, X; Manier, S; Mishima, Y; Reagan, M; Roccaro, AM; Sacco, A; Wang, YE; Zhang, W; Zhang, Y1
De Bruyne, E; De Smedt, E; Hose, D; Kassambara, A; Klein, B; Maes, K; Menu, E; Moreaux, J; Seckinger, A; Van Valckenborgh, E; Vanderkerken, K1
Chim, CS; Li, ZY; Wang, LQ; Wong, KY; Zhang, Q1
Adomako, A; Aguirre-Ghiso, JA; Biran, N; Calvo, V; Chari, A; Moore, K; Osman, K; Paton, AW; Paton, JC; Schewe, DM1
Gopinadh, J; Klar, AS; Kleber, S; Renner, C; Wadle, A1
Jing, HM; Liu, YY; Wang, J; Wang, WM; Wang, YF; Zhu, MX1
Cao, Y; Gu, WY; Lin, Y; Qiu, GQ; Wang, ZL; Wu, HQ; Wu, W; Xie, XB1
Jernberg-Wiklund, H; Nilsson, K; Oberg, F; Tshuikina, M1
Chang, HR; Chen, GH; Huang, HW; Lin, FR; Wang, Y; Wu, DP1
Asaoku, H; Hayashi, T; Imai, K; Ishida, T; Maruyama, R; Maruyama, Y; Mori, M; Nojima, M; Sakai, H; Sasaki, Y; Shinomura, Y; Suzuki, H; Tarasawa, I; Tokino, T; Toyota, M; Yasui, H1
Chang, WR; Chen, GH; Feng, YF; Huang, HW; Lin, FR; Tang, XW; Wang, Y; Wu, DP; Zhu, ZL1
Almstedt, M; Blagitko-Dorfs, N; Duque-Afonso, J; Jäger, E; Karbach, J; Lübbert, M; Pfeifer, D1
Bartova, E; Hajek, R; Harnicarova-Horakova, A; Kozubek, S; Legartova, S; Pour, L1
Barlogie, B; Garg, T; Hoerring, A; Moreno-Bost, A; Prentice, HG; Shaughnessy, J; Stone, K; Szmania, S; Szymonifka, J; van Rhee, F1
Chim, CS; Chung, LP; Jin, DY; Lam, WW; Li, GK; Liang, R; Loong, F; So, CC; Wong, KY1
Bártová, E; Jugová, A; Kozubek, S; Legartová, S; Stixová, L; Sustáčková, G1
Khong, T; Spencer, A1
Chen, JF; Dong, CX; Feng, DW; Guo, ZP; Wang, MF; Yang, LH; Zhagn, L; Zhang, JH; Zhang, RJ1
Brümmendorf, TH; Galm, O; Herman, JG; Jost, E; Lentjes, MH; van Engeland, M; van Gemmeren, TB; Wilop, S1
Chim, CS; Jin, DY; Liang, R; So, CC; Wong, KY; Yim, RL1
Groen, RW; Kersten, MJ; Kocemba, KA; Mahtouk, K; Pals, ST; Spaargaren, M; van Andel, H1
Hu, JP; Hu, WX; Li, J; Luo, SQ; Qu, Q; Ren, W; Zhang, JM; Zhong, Y1
Chung, HM; Clark, WB; Hazlett, AF; Kmieciak, M; Manjili, MH; McCarty, JM; Payne, KK; Roberts, CH; Sabo, RT; Sanford, K; Toor, AA; Williams, DC1
Goldschmidt, H; Hose, D; Klein, B; Leonard, W; Moreaux, J; Rème, T; Requirand, G; Veyrune, JL1
Amodio, N; Bellizzi, D; Caraglia, M; D'Aquila, P; Di Martino, MT; Fabiani, F; Giordano, A; Gullà, AM; Leone, E; Leotta, M; Lionetti, M; Negrini, M; Neri, A; Passarino, G; Tagliaferri, P; Tassone, P1
Chen, J; Peng, L; Ren, G; Tan, C; Yang, Z1
Chen, H; Du, HL; Qi, Y; Ren, LM; Zhu, Y1
Bu, DF; Du, HL; Qi, Y; Shi, YJ; Wu, SL1
Chen, YH; DeSimone, J; Hankewych, M; Kousnetzova, T; Lavelle, D1
Drach, J; Feng, Z; Gazdar, AF; Kroft, SH; McKenna, RW; Miyajima, K; Parikh, G; Reddy, J; Shigematsu, H; Shivapurkar, N; Suzuki, M; Takahashi, T; Timmons, C; Toyooka, S; Zheng, Y; Zöchbauer-Müller, S1
Bowen, D; Lim, SH; Ramsahoye, B; Wang, Z; Zhang, Y1
Cherry, JC; Farrar, WL; Fox, SD; Hodge, DR; Hurt, EM; Kelley, JA; Munroe, DJ; Peng, B1
Lim, SH; Wang, Z; Zhang, J; Zhang, Y1
Chen, BB; Chen, Q; Chen, YM; Song, YF; Xie, Y; Xu, R; Zhang, XH1
Hata, H; Mitsuya, H; Okuno, Y; Takeya, M; Tatetsu, H; Tenen, DG; Ueno, S; Yamada, Y1
Chim, CS; Choi, CL; Fung, TK; Kwong, YL; Liang, R1
Anderson, KC; Catley, L; Chauhan, D; Hideshima, T; Ikeda, H; Ishitsuka, K; Kiziltepe, T; Ocio, EM; Okawa, Y; Pozzi, S; Raje, N; Shiraishi, N; Vallet, S; Yasui, H1
Chim, CS; Choi, CL; Fung, TK; Liang, R; Pang, R1
Bilban, M; Drach, J; Heller, G; Holzer, S; Müllauer, L; Schmidt, WM; Ziegler, B; Zielinski, CC; Zöchbauer-Müller, S1
Khong, T; Sharkey, J; Spencer, A1
Farmer, B; Lim, SH; Wang, Z; Zhang, J; Zhang, Y1
Diamant, M; Due, C; Olsson, L1

Trials

2 trial(s) available for azacitidine and Multiple Myeloma

ArticleYear
Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study).
    Leukemia & lymphoma, 2019, Volume: 60, Issue:9

    Topics: Adaptor Proteins, Signal Transducing; Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dexamethasone; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Progression-Free Survival; Proteomics; Ubiquitin-Protein Ligases

2019
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.
    British journal of haematology, 2012, Volume: 158, Issue:6

    Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boronic Acids; Bortezomib; Dexamethasone; DNA Methylation; Doxorubicin; Drug Administration Schedule; Epigenesis, Genetic; Female; Humans; Immunity, Cellular; Lenalidomide; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Prospective Studies; Pyrazines; T-Cell Antigen Receptor Specificity; Thalidomide; Transplantation, Autologous

2012

Other Studies

59 other study(ies) available for azacitidine and Multiple Myeloma

ArticleYear
[Effect of miR-203/CREB1 Signaling Regulation Mediated by DNA Methylation on the Proliferation and Apoptosis of Multiple Myeloma Cells].
    Zhongguo shi yan xue ye xue za zhi, 2022, Volume: 30, Issue:3

    Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Multiple Myeloma; RNA, Messenger

2022
Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment.
    Leukemia research, 2022, Volume: 122

    Topics: ABO Blood-Group System; Antibodies, Monoclonal; Antineoplastic Agents; Azacitidine; Blood Transfusion; Dithiothreitol; Humans; Multiple Myeloma

2022
The Effect of Ras Homolog C/Rho-Associated Coiled-Protein Kinase (Rho/ROCK) Signaling Pathways on Proliferation and Apoptosis of Human Myeloma Cells.
    Medical science monitor : international medical journal of experimental and clinical research, 2019, Oct-10, Volume: 25

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Humans; Hydroxamic Acids; Multiple Myeloma; Protein Kinase Inhibitors; rho GTP-Binding Proteins; rho-Associated Kinases; RNA, Messenger; Signal Transduction

2019
Spider-like injection site reaction after subcutaneous administration of haematological treatments.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2020, Volume: 34, Issue:3

    Topics: Antineoplastic Agents; Azacitidine; Bortezomib; Humans; Injections, Subcutaneous; Male; Multiple Myeloma; Skin

2020
Synchronous detection of multiple myeloma and acute myeloid leukemia: A diagnostic and therapeutic challenge.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:2

    Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Arm; Azacitidine; Biopsy; Bone Marrow; Bortezomib; Dexamethasone; Fatal Outcome; Granulocyte Precursor Cells; Humans; Leukemia, Myeloid, Acute; Male; Multiple Myeloma; Myeloma Proteins; Necrosis

2021
Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.
    Annals of hematology, 2017, Volume: 96, Issue:8

    Topics: Aged; Anemia, Macrocytic; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; In Situ Hybridization, Fluorescence; Janus Kinase 2; Leukemia, Myeloid, Acute; Multiple Myeloma; Mutation, Missense; Neoplasms, Multiple Primary; Remission Induction; Translocation, Genetic

2017
Epigenetic silencing of LPP/miR-28 in multiple myeloma.
    Journal of clinical pathology, 2018, Volume: 71, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; CpG Islands; Cytoskeletal Proteins; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; LIM Domain Proteins; Male; MicroRNAs; Middle Aged; Multiple Myeloma; Promoter Regions, Genetic

2018
"Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
    Blood, 2017, 09-28, Volume: 130, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cyclophosphamide; Cytoplasm; Dexamethasone; Diagnostic Errors; Erythroblasts; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Erythroblastic, Acute; Male; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide

2017
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
    Molecular oncology, 2018, Volume: 12, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Chromatin; DNA Methylation; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression; Gene Expression Profiling; Humans; Lenalidomide; Morpholines; Multiple Myeloma; Peptide Hydrolases; Pyridones; Thalidomide; Ubiquitin-Protein Ligases

2018
Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.
    International journal of molecular sciences, 2017, Dec-23, Volume: 19, Issue:1

    Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Cisplatin; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Melphalan; Multiple Myeloma; Tumor Protein p73; Tumor Suppressor Protein p53

2017
Epigenetic silencing of miR-335 induces migration by targeting insulin-like growth factor-1 receptor in multiple myeloma.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Case-Control Studies; Cell Line, Tumor; Cell Movement; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Healthy Volunteers; Humans; MicroRNAs; Middle Aged; Multiple Myeloma; Promoter Regions, Genetic; Receptor, IGF Type 1

2019
Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.
    Leukemia research, 2013, Volume: 37, Issue:8

    Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Decitabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Hydrogen Peroxide; Hydroxamic Acids; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxidants; Prognosis; Pyrazines; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; Scavenger Receptors, Class A

2013
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.
    Blood, 2013, Jul-11, Volume: 122, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Chromosome Aberrations; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Male; Middle Aged; Multiple Myeloma; Osteonectin; Phenotype; Prognosis; Transforming Growth Factor beta1; Tumor Suppressor Proteins

2013
Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
    Cell death & disease, 2013, Sep-12, Volume: 4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Biphenyl Compounds; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Mice; Mice, Inbred C57BL; Mice, Transgenic; Multiple Myeloma; Nitrophenols; Panobinostat; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Receptors, Death Domain; Recombinant Proteins; Sulfonamides; TNF-Related Apoptosis-Inducing Ligand

2013
DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine.
    British journal of haematology, 2014, Volume: 164, Issue:4

    Topics: Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Drug Screening Assays, Antitumor; Epigenomics; Humans; Multiple Myeloma; Predictive Value of Tests

2014
Effect of 5-aza-2'-deoxycytidine combined with trichostatin A on RPMI-8226 cell proliferation, apoptosis and DLC-1 gene expression.
    Zhongguo shi yan xue ye xue za zhi, 2014, Volume: 22, Issue:2

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; Gene Expression; GTPase-Activating Proteins; Humans; Hydroxamic Acids; Multiple Myeloma; Tumor Suppressor Proteins

2014
Down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Azacitidine; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Tetraspanin 29

2014
The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.
    Oncotarget, 2014, May-30, Volume: 5, Issue:10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Blotting, Western; Decitabine; Disease Models, Animal; DNA Damage; DNA Repair; Flow Cytometry; Fluorescent Antibody Technique; Homologous Recombination; Humans; Hydroxamic Acids; Mice; Mice, Inbred C57BL; Multiple Myeloma; Real-Time Polymerase Chain Reaction

2014
Global epigenetic regulation of microRNAs in multiple myeloma.
    PloS one, 2014, Volume: 9, Issue:10

    Topics: Apoptosis; Azacitidine; beta-Transducin Repeat-Containing Proteins; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA-Binding Proteins; E2F3 Transcription Factor; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Multiple Myeloma; RNA, Messenger; Transcription Factors

2014
In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
    Oncotarget, 2015, Feb-20, Volume: 6, Issue:5

    Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Computational Biology; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice, Inbred C57BL; Molecular Targeted Therapy; Multiple Myeloma; Transcription, Genetic; Treatment Outcome

2015
Infrequent DNA methylation of miR-9-1 and miR-9-3 in multiple myeloma.
    Journal of clinical pathology, 2015, Volume: 68, Issue:7

    Topics: Azacitidine; Biomarkers, Tumor; Case-Control Studies; Cell Line, Tumor; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; MicroRNAs; Multiple Myeloma; Phenotype; Promoter Regions, Genetic; Recurrence; Treatment Outcome

2015
Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment.
    BMC cancer, 2015, May-30, Volume: 15

    Topics: Adult; Aged; Animals; Apoptosis; Azacitidine; Bortezomib; Cell Survival; Cyclin-Dependent Kinase 6; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Male; Mice; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; p21-Activated Kinases; Xenograft Model Antitumor Assays

2015
Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.
    PloS one, 2015, Volume: 10, Issue:10

    Topics: Antigens, Neoplasm; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; Female; HLA-A2 Antigen; Humans; Immunotherapy; Interferon-gamma; MCF-7 Cells; Membrane Proteins; Microscopy, Fluorescence; Multiple Myeloma; Peptides; Real-Time Polymerase Chain Reaction; Receptors, Antigen, T-Cell; T-Lymphocytes, Cytotoxic; Up-Regulation

2015
[Inductive Effect of 5-Azacitidine on Apoptosis of Multiple Myeloma Cell lines and Its Mechanism].
    Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:1

    Topics: Apoptosis; Azacitidine; bcl-2-Associated X Protein; Caspase 3; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Humans; MAP Kinase Signaling System; Multiple Myeloma; Proto-Oncogene Proteins c-bcl-2

2016
Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells.
    Molecular medicine reports, 2016, Volume: 14, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Bortezomib; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Poly(ADP-ribose) Polymerases

2016
Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma.
    Experimental hematology, 2008, Volume: 36, Issue:12

    Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Interferon Regulatory Factors; Multiple Myeloma; Neoplasm Proteins; Promoter Regions, Genetic

2008
Preliminary study on 5-azacytidine anti-myeloma activity in vitro.
    Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Cell Proliferation; Humans; Intracellular Signaling Peptides and Proteins; Multiple Myeloma; Neoplasm Proteins; Promoter Regions, Genetic

2009
Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jul-01, Volume: 15, Issue:13

    Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cell Survival; Decitabine; Dexamethasone; DNA Methylation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genetic Testing; Humans; Models, Biological; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; ras Proteins

2009
[5-azacytidine treatment induces tumor suppressor gene XAF1 expression and inhibits proliferation in myeloma cells].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2009, Volume: 30, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Cell Proliferation; CpG Islands; DNA Methylation; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Multiple Myeloma; Neoplasm Proteins

2009
The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
    Leukemia research, 2010, Volume: 34, Issue:7

    Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Chromosomes, Human, X; Decitabine; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Leukemic; Genes, X-Linked; HL-60 Cells; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Melanoma-Specific Antigens; Membrane Proteins; Multiple Myeloma; Neoplasm Proteins; RNA, Messenger; RNA, Neoplasm; U937 Cells

2010
Expression of RAN, ZHX-2, and CHC1L genes in multiple myeloma patients and in myeloma cell lines treated with HDAC and Dnmts inhibitors.
    Neoplasma, 2010, Volume: 57, Issue:5

    Topics: Azacitidine; Cell Line, Tumor; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Hydroxamic Acids; Multiple Myeloma; Neoplasm Proteins; ran GTP-Binding Protein; Transcription Factors

2010
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
    Cytotherapy, 2011, Volume: 13, Issue:5

    Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Cell Line, Tumor; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Male; Multiple Myeloma; Neoplasm Proteins; Pyrimidines; Secondary Prevention; T-Lymphocytes, Cytotoxic

2011
Epigenetic inactivation of the miR-124-1 in haematological malignancies.
    PloS one, 2011, Apr-22, Volume: 6, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase 6; Epigenesis, Genetic; Female; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methylation; MicroRNAs; Middle Aged; Multiple Myeloma; Reverse Transcriptase Polymerase Chain Reaction; Young Adult

2011
Effects of epigenetic-based anti-cancer drugs in leukaemia and multiple myeloma cells.
    Cell biology international, 2011, Volume: 35, Issue:12

    Topics: Antineoplastic Agents; Azacitidine; Chromobox Protein Homolog 5; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Silencing; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Leukemia; Multiple Myeloma; Retinoblastoma Protein; Tumor Suppressor Protein p53

2011
Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Checkpoints; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; G1 Phase; HSP90 Heat-Shock Proteins; Humans; MAP Kinase Kinase Kinases; Multiple Myeloma; Pyrazines; Pyridones; Pyrimidines; Signal Transduction; STAT3 Transcription Factor

2011
[Effects of decitabine on biological behavior of U266 cells].
    Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:4

    Topics: Apoptosis; Azacitidine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Decitabine; Humans; Multiple Myeloma

2011
Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma.
    Epigenetics, 2011, Volume: 6, Issue:8

    Topics: Aged; Azacitidine; Bone Marrow; Cell Line, Tumor; CpG Islands; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Middle Aged; Multiple Myeloma; Neoplasm Staging; Promoter Regions, Genetic; Sequence Analysis, DNA; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins

2011
Epigenetic inactivation of the MIR34B/C in multiple myeloma.
    Blood, 2011, Nov-24, Volume: 118, Issue:22

    Topics: Azacitidine; Base Sequence; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; MicroRNAs; Molecular Sequence Data; Multiple Myeloma; Primary Cell Culture; Recurrence; Tumor Cells, Cultured

2011
Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma.
    PloS one, 2012, Volume: 7, Issue:2

    Topics: Azacitidine; Base Sequence; Bone Marrow; Cell Line, Tumor; Disease Progression; DNA Methylation; Gene Silencing; Humans; Intercellular Signaling Peptides and Proteins; Molecular Sequence Data; Multiple Myeloma; Neoplasm Staging; Promoter Regions, Genetic; Transcription, Genetic; Wnt Proteins; Wnt Signaling Pathway

2012
The effects of promoter methylation on downregulation of DAZAP2 in multiple myeloma cell lines.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: Animals; Azacitidine; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Multiple Myeloma; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA-Binding Proteins; Sequence Analysis, DNA; Transcription, Genetic

2012
Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:12

    Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Predictive Value of Tests; Prognosis

2012
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma.
    Oncotarget, 2012, Volume: 3, Issue:10

    Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Biomimetics; Blotting, Western; Bone Marrow; Case-Control Studies; Cell Cycle; Cell Proliferation; Cellular Microenvironment; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Leukemia, Plasma Cell; Male; Mice; Mice, SCID; MicroRNAs; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured

2012
Epigenetic inactivation of ADAMTS9 via promoter methylation in multiple myeloma.
    Molecular medicine reports, 2013, Volume: 7, Issue:3

    Topics: ADAM Proteins; ADAMTS9 Protein; Adult; Aged; Azacitidine; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Female; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; S Phase Cell Cycle Checkpoints

2013
Re-expression of p16 gene in the myeloma cell line U266 induced by synergy of sodium butyrate and 5-Aza-2'-deoxycytidine.
    Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, 2002, Volume: 22, Issue:11

    Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Butyrates; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; Drug Synergism; Gene Expression; Humans; Multiple Myeloma; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured

2002
[Apoptosis and re-expression of p16 gene in the myeloma cell line U266 induced by synergy of histone deacetylase inhibitor and demethylating agent].
    Ai zheng = Aizheng = Chinese journal of cancer, 2002, Volume: 21, Issue:10

    Topics: Annexin A5; Apoptosis; Azacitidine; Blotting, Western; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Modification Methylases; DNA, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Phenylbutyrates; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured

2002
Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway.
    Leukemia research, 2003, Volume: 27, Issue:11

    Topics: Antimetabolites, Antineoplastic; Azacitidine; Carrier Proteins; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; G1 Phase; Kinetics; Leukemia, Lymphoid; Mitosis; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Tumor Cells, Cultured

2003
DNA methylation profiles of lymphoid and hematopoietic malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, May-01, Volume: 10, Issue:9

    Topics: Age Factors; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Leukemia; Logistic Models; Lymphoma; Male; Middle Aged; Multiple Myeloma; Promoter Regions, Genetic; Sex Factors

2004
Sp17 gene expression in myeloma cells is regulated by promoter methylation.
    British journal of cancer, 2004, Oct-18, Volume: 91, Issue:8

    Topics: Antigens, Surface; Antimetabolites, Antineoplastic; Azacitidine; Calmodulin-Binding Proteins; Carrier Proteins; Chloramphenicol O-Acetyltransferase; CpG Islands; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Multiple Myeloma; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Transcription, Genetic; Tumor Cells, Cultured

2004
Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation.
    Cancer research, 2005, Jun-01, Volume: 65, Issue:11

    Topics: Apoptosis; Azacitidine; Base Sequence; Cell Cycle; Cell Line, Tumor; Cytidine; Decitabine; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Silencing; Genes, p53; Humans; Interleukin-6; Molecular Sequence Data; Multiple Myeloma; Promoter Regions, Genetic; Sulfites; Tumor Suppressor Protein p53

2005
SPAN-Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically.
    International journal of cancer, 2006, Mar-15, Volume: 118, Issue:6

    Topics: Azacitidine; Blotting, Western; Cell Line, Tumor; Chloramphenicol O-Acetyltransferase; CpG Islands; DNA Methylation; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Interleukin-4; Interleukin-7; K562 Cells; Multiple Myeloma; Nuclear Proteins; Promoter Regions, Genetic; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transfection; Tumor Cells, Cultured

2006
High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma.
    Journal of clinical pathology, 2006, Volume: 59, Issue:9

    Topics: Azacitidine; Base Sequence; Bone Marrow; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; GTPase-Activating Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; Molecular Sequence Data; Multiple Myeloma; Neoplasm Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Tumor Suppressor Proteins; Up-Regulation

2006
Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.
    Cancer research, 2007, Jun-01, Volume: 67, Issue:11

    Topics: Apoptosis; Azacitidine; Base Sequence; Cell Growth Processes; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Introns; Molecular Sequence Data; Multiple Myeloma; Prognosis; Promoter Regions, Genetic; Proto-Oncogene Proteins; Regulatory Elements, Transcriptional; Trans-Activators; Up-Regulation

2007
Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma.
    Journal of clinical pathology, 2007, Volume: 60, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; Azacitidine; Base Sequence; Biomarkers, Tumor; Calcium-Calmodulin-Dependent Protein Kinases; Death-Associated Protein Kinases; DNA Methylation; DNA, Neoplasm; Epigenesis, Genetic; Female; Humans; Male; Middle Aged; Molecular Sequence Data; Multiple Myeloma; Neoplasm Proteins; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins c-mdm2; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2007
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; DNA Damage; DNA, Neoplasm; Doxorubicin; Drug Synergism; Enzyme Inhibitors; Humans; Multiple Myeloma; Pyrazines

2007
Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma.
    Leukemia, 2007, Volume: 21, Issue:12

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Azacitidine; Base Sequence; beta Catenin; Cell Line, Tumor; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Molecular Sequence Data; Multiple Myeloma; Neoplasm Proteins; Phosphorylation; Protein Processing, Post-Translational; Recombinant Proteins; Signal Transduction; Wnt Proteins

2007
Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
    Cancer research, 2008, Jan-01, Volume: 68, Issue:1

    Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Genome, Human; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Multiple Myeloma; Transcription, Genetic; Tumor Cells, Cultured

2008
The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma.
    Haematologica, 2008, Volume: 93, Issue:6

    Topics: Active Transport, Cell Nucleus; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; bcl-X Protein; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Interleukin-6; Multiple Myeloma; NF-kappa B; Phosphorylation; Signal Transduction; STAT3 Transcription Factor; Tetrazolium Salts

2008
Semenogelin I expression in myeloma cells can be upregulated pharmacologically.
    Leukemia research, 2008, Volume: 32, Issue:12

    Topics: Azacitidine; Bone Marrow; Cytokines; Gene Expression Regulation, Neoplastic; Humans; Interleukin-4; Interleukin-6; Male; Multiple Myeloma; Plasmids; Promoter Regions, Genetic; Restriction Mapping; Semen; Seminal Vesicle Secretory Proteins; Transfection; Up-Regulation

2008
Treatment of human cell lines with 5-azacytidine may result in profound alterations in clonogenicity and growth rate.
    The Journal of cell biology, 1985, Volume: 100, Issue:2

    Topics: Azacitidine; Carcinoma, Squamous Cell; Cell Division; Cell Line; Cells, Cultured; Clone Cells; Humans; Lung Neoplasms; Lymphoma; Multiple Myeloma

1985